[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-adherence-medication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-adherence-medication":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100588225","addressing-medication-non-adherence-in-patients-with-poorly-controlled-hypertension-using-urine-mass-spectrometry-100588225",false,"NCT06938633","Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry","Utility of Urine Mass Spectrometry Analysis in Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension","ADURINE","Inclusion Criteria:\n\n1. Age of 21 - 80 years\n2. Systolic blood pressure of ≥140 mmHg or average systolic blood pressure ≥135 mmHg, or diastolic blood pressure ≥90 mmHg or average diastolic blood pressure ≥85 mmHg, on at least two measurements\n3. Currently taking 2 or more hypertension medications\n4. Able to provide informed consent.\n\nExclusion Criteria:\n\n* Significant kidney impairment with eGFR of less than 45mL\u002Fmin\u002F1.73m2 or on dialysis\n* Known history of chronic liver disease","ALL","21 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","* Hypertension is the single largest contributor to cardiovascular disease and death. While adequate control of hypertension reduces risk of disease, many patients have uncontrolled hypertension. This is often due to medication non-adherence. Left undetected, patients are prescribed additional medications, and referred to multiple specialists for investigations - leading to increased healthcare costs. Hence, detecting non-adherence to antihypertensive medications is important. However, patient history, patient recall, or questionnaires, are often inaccurate. Most recently, urine measurements of antihypertensive drug levels, using mass spectrometry, has been established as the gold standard to assess medication adherence. The one-time urine test for medication adherence is ideal: It's convenient, non-invasive, economical, and can be easily performed in a clinic setting. By improving blood pressure control, this will lead to reductions in healthcare visits, avoidance of catastrophic cardiovascular events. Ultimately, this translates to significant economic savings for both patients with hypertension and the healthcare system.\n* Therefore, the investigators hypothesize that the implementation of urine adherence testing coupled with targeted counselling will improve the adherence and blood pressure control in hypertension. To do this, the investigators aim to (1) evaluate for medication adherence in 312 participants with recent stroke and hypertension; (2) evaluate for medication non-adherence in participants with uncontrolled hypertension; and (3) assess if detection of non-adherence can improve hypertension control.",[28,29,30],"Hypertension","Uncontrolled Hypertension","Non-Adherence, Medication",[32,33,34],"Urine mass spectrometry","Uncontrolled hypertension","Medication non-adherence","RECRUITING","2025-04-14",{"date":38,"type":39},"2025-04-22","ACTUAL",{"date":41,"type":39},"2024-02-07",{"date":43,"type":22},"2025-09-30",{"name":45,"class":46},"Changi General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100555051","phase-3-outcomes-of-the-plhiv-with-suboptimal-viral-suppression-to-injectable-long-acting-antiretrovirals-100555051","NCT06507059","Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals","A Phase 3 Study Comparing Clinical Outcomes in People Living With HIV (PLHIV) With Suboptimal Adherence Treated With Injectable Long-acting Antiretrovirals Versus Oral Antiretrovirals","SUPLA","Inclusion Criteria:\n\n* Willing to sign the written informed consent form for male and female participants aged 18 and above.\n* At the time of enrollment, diagnosed with HIV infection for a minimum of 12 months.\n* Under oral antiretroviral treatment (ART), which can be irregular or interrupted, with the most recent viral load ≥ 200 copies\u002FmL.\n* Body weight ≥ 35Kg.\n* Willing to maintain contact with the research team throughout the study (provide accurate and reachable phone numbers, social accounts like Line, or reliable contact information of family or friends).\n* Willing to receive gluteal (buttocks) drug injections.\n* Willing to transition back to oral medication or follow the recommended treatment prescription according to the then-current national treatment guidelines after discontinuation of long-acting injectable drugs.\n\nExclusion Criteria:\n\n* For those currently undergoing oral antiretroviral therapy, who have started or restarted oral ART for less than six consecutive months before screening.\n* Previously undergone HIV drug resistance testing and known to have resistance mutations to either cabotegravir or rilpivirine.\n* Unable to commit to maintaining contact with the research team throughout the study.\n* Individuals who cannot receive treatment for hepatitis B during the period of transitioning to long-acting injections, if they are hepatitis B carriers.\n* Individuals with buttock fillers.\n* Women who are planning to become pregnant, pregnant, or currently breastfeeding.","18 Years",{"count":58,"type":22},40,[60],"PHASE3","This study aims to determine whether people living with HIV (PLHIV) with suboptimal medical adherence can achieve better viral suppression with long-acting antiretrovirals (LA) compared to all-oral antiretrovirals.",[63,30],"HIV-1-infection",[65],"HIV-1, non-adherence","2024-08-21",{"date":68,"type":39},"2024-08-23",{"date":70,"type":39},"2024-07-19",{"date":72,"type":22},"2026-12-31",{"name":74,"class":46},"Chang Gung Memorial Hospital",4]